What is Invitae?
Invitae is a medical genetics company dedicated to providing accessible and comprehensive genetic testing. Operating primarily in the United States, the company processes DNA-containing samples from at-home test kits to analyze patient-specific genetic variations. The resulting test reports are then provided to clinicians and their patients, facilitating informed healthcare decisions. Founded in 2010 and headquartered in San Francisco, California, Invitae aims to integrate genetic information into routine medical care, thereby improving patient outcomes and advancing the understanding of genetic diseases.
How much funding has Invitae raised?
Invitae has raised a total of $1.2B across 11 funding rounds:
Series F
$120M
Stock Offering
$116.8M
Share Placement
$73.5M
Debt
$40M
Stock Offering
$53.5M
Stock Offering
$196.7M
Debt
$291.2M
Stock Offering
$184M
Share Placement
$30M
Series F (2014): $120M supported by Perceptive Advisors, Thomas McNerney & Partners, Genesys Capital, Deerfield, Randy Scott, Decheng Capital, Redmile Group, Rock Springs Capital, Casdin Capital, OrbiMed, Wellington Management, Genomic Health, and The Broe Group
Stock Issuance/Offering (2015): $116.8M featuring Undisclosed
Share Placement (2017): $73.5M backed by Undisclosed
Debt (2018): $40M with participation from Oxford Finance
Stock Issuance/Offering (2018): $53.5M led by Undisclosed
Stock Issuance/Offering (2019): $196.7M supported by Undisclosed
Debt (2019): $291.2M featuring Undisclosed
Stock Issuance/Offering (2020): $184M backed by Undisclosed
Share Placement (2023): $30M, investors not publicly disclosed
Key Investors in Invitae
Perceptive Advisors
Perceptive Advisors, founded in 1999 and based in New York, NY, is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
Thomas McNerney & Partners
Thomas, McNerney & Partners is a health care venture firm with approximately $600 million under management, focused on investing in innovative life science and medical technology companies at all stages of development.
Genesys Capital
Genesys Capital is a Torontobased venture capital firm focused on earlystage life sciences and healthcare companies, raising dedicated VC funds and investing in biotechnology and medical innovation across North America.
What's next for Invitae?
The recent major strategic investment of $30M positions Invitae for accelerated expansion and innovation. This capital infusion, part of its overall $1.2B in funding, will likely be directed towards enhancing its genomic analysis platforms, expanding its service offerings, and potentially pursuing strategic partnerships or acquisitions. As the demand for genetic testing continues to grow, driven by advancements in personalized medicine and a greater understanding of genetic predispositions, Invitae is poised to leverage this investment to solidify its leadership in the market and further its mission of making genetic information more actionable for healthcare providers and patients alike.
See full Invitae company page
